← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT06961071

Parathyroid Allotransplant for Treatment of Hypoparathyroidism

Trial Parameters

Condition Hypoparathyroidism
Sponsor Peter Stock
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 3
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2026-01-15
Completion 2028-01-15
Interventions
Parathyroid Allotransplant

Brief Summary

This study is being done to see if transplanting parathyroid tissue into the forearm will help hypo-parathyroid patients achieve parathyroid hormone (PTH) levels that would help normalize their serum calcium and phosphorus levels. The parathyroid tissue used in this study will come from cadaveric tissues that were donated at the time of the death of the donor(s).

Eligibility Criteria

Inclusion Criteria Only subjects who meet all of the following criteria are eligible for enrollment. 1. Subjects age 18 or older. 2. Subjects who are able to provide written informed consent and to comply with study procedures. 3. Clinical history and laboratory data compatible with HypoPT as defined by hypocalcemia and documented PTH levels either inappropriately normal or below the normal range on two occasions greater than 2 weeks apart and 12 months after surgery, requiring treatment with activated vitamin D (≥0.5 mcg calcitrol) and oral calcium (≥800mg) daily, or currently on PTH (1-84), PTH (1-34), palopegteriparatide or other recombinant parathyroid hormone replacement injections with ongoing symptomatology due to hypocalcemia and variable degree of biochemical control. 4. No history of immunodeficiency (e.g., opportunistic infections) that could be exacerbated by immunosuppression. 5. Up to date immunizations per the University of California, San Francisco (UCSF) standard of ca

Related Trials